SCHEMBL1818951

SCHEMBL1818951

CCN(CC)c1ccccc1C(C)(Oc1ccccc1)C(N)=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.35
MAPT P10636 1/20 0.35
PPARA Q07869 5/20 0.34
PPARG P37231 4/20 0.33
CHRM2 P08172 3/20 0.33
CHRM3 P20309 3/20 0.33
MEN1 O00255 3/20 0.33
KDM4E B2RXH2 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
NOX1 Q9Y5S8 2/20 0.33
RARA P10276 1/20 0.32
RARB P10826 1/20 0.32
RARG P13631 1/20 0.32
CHRM4 P08173 1/20 0.32
CHRM5 P08912 1/20 0.32
CHRM1 P11229 1/20 0.32
ALPL P05186 1/20 0.32
ALPI P09923 1/20 0.32
ALPG P10696 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1819317 0.87 LMNA (0.38) MAPTPPARAPPARGKDM4EL3MBTL1
SCHEMBL1819565 0.85 MAPT (0.38) KMT2AMAPTPPARAPPARGCHRM2
SCHEMBL1819040 0.77 MAPT (0.41) KMT2AMAPTPPARAPPARGMEN1
SCHEMBL1818643 0.77 ALDH1A1 (0.44) KMT2AMAPTPPARAPPARGMEN1
SCHEMBL1823517 0.76 MAPT (0.40) KMT2AMAPTPPARAPPARGMEN1
SCHEMBL1821869 0.76 KCNN4 (0.51) KMT2AMAPTPPARAPPARGNPC1
SCHEMBL1819713 0.76 MAOB (0.42) KMT2AMAPTMEN1
SCHEMBL1821619 0.74 CTNNB1 (0.49) KMT2AMAPTPPARGKDM4ETSPO
SCHEMBL1818709 0.74 KMT2A (0.44) KMT2AMAPTMEN1KDM4EL3MBTL1
SCHEMBL1817766 0.73 CYP2C19 (0.38) KMT2AMAPTPPARAPPARGL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947712-B2 Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent WYETH LLC (US) 2011-05-24 US disclosed
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof WYETH (US) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof MMP8, MMP26, MMP9 KMT2A 4052/4885MAPT 2414/4885PPARA 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.